PMCPA Case Library

Over 2,000+ real adjudications. Browse free — subscribe to search by company, clause and case reference.

Search by company, clause, case ref…🔒
Filter by clause…🔒
Filter by company…🔒

1,914 cases  ·  Unlock search, clause & company filters ↓

2023
year
AUTH/3836/10/23 GlaxoSmithKline Clause 5.1 Clause 6.1

GSK breached ABPI Code over Zejula AE management webpage that omitted discontinuation scenarios

PMCPA ruled GSK’s Zejula “PRIMA AE management” webpage misleading for implying AEs could be managed by dose interruption/modification without highlighting…

2023
year
AUTH/3790/7/23 Moderna ⭐ Case of the Week

AUTH/3790/7/23: Ex-employee v Moderna (preprint data in presentations) — No breach

Anonymous ex-employee alleged Moderna misused preprint vaccine effectiveness data, cherry-picked graphs and sought UK contract advantage via JCVI presentations. Panel…

2023
year
AUTH/3854/11/23 GlaxoSmithKline Clause 11.2 Clause 26.1 Clause 5.1

GSK: LinkedIn ‘celebrate’ of third‑party niraparib trial post ruled off‑label promotion to the public (AUTH/3854/11/23)

A UK-based GSK Global employee ‘celebrated’ a third-party LinkedIn post about promising niraparib results in glioblastoma. PMCPA found promotion to…

2023
year
AUTH/3864/12/23 Celltrion Healthcare UK Clause 17.2 Clause 18.2

Celltrion: representative’s unsubstantiated “cost neutral” NICE/TAG justification and failure to provide substantiation for Remsima SC

A pharmacist complained about a rep’s claim that NICE said infliximab SC fell under infliximab IV TAG due to cost…

2024
year
AUTH/3901/5/24 GlaxoSmithKline

AUTH/3901/5/24: Complainant v GSK — Jemperli HCP website (mobile vs desktop certification and “manageable safety profile” claim) — No breach

Complaint alleged Jemperli HCP webpages weren’t properly certified for mobile due to layout/navigation differences and that a “manageable safety profile”…

2024
year
AUTH/3922/6/24 GlaxoSmithKline

AUTH/3922/6/24: Complainant v GSK — Trelegy banner alleged off-label switch claim (No breach)

Complaint alleged a Trelegy Ellipta rotating banner promoted an unlicensed switch from three inhalers (incl. SABA). PMCPA Panel found no…

2008
year
AUTH/2078/1/08 Pfizer Clause 1.2 Clause 4.1

Pfizer letter requesting addition of Ecalta and Celsentri to hospital e-prescribing system ruled promotional without prescribing information

A hospital pharmacist complained about a Pfizer-authorised letter asking hospitals to add Ecalta and Celsentri to electronic prescribing/dispensing systems. The…

2008
year
AUTH/2106/3/08 Trinity-Chiesi Pharmaceuticals

Trinity-Chiesi letter promoting Clenil: omission of 200mcg cost comparison not misleading in Scottish context

A PCT pharmacist alleged a Clenil cost-comparison chart was misleading because it omitted 200mcg data. The Panel found the Scottish…

2008
year
AUTH/2156/8/08 Sanofi Clause 9.1

AUTH/2156/8/08: GlaxoSmithKline v Sanofi Pasteur MSD – Gardasil letter to health professionals

A letter about the UK HPV vaccine tender was ruled promotional for Gardasil, lacked prescribing information and adverse event reporting…

2008
year
AUTH/2141/7/08 Sanofi Clause 1 Clause 2 Clause 24 ⭐ Case of the Week

AUTH/2141/7/08: Novo Nordisk v Sanofi-Aventis – Promotion of Lantus (24-hour efficacy and hypoglycaemia claims)

Complaint about Lantus promotional leavepieces and a mailer. Issues included “24-hour efficacy” wording and comparative hypoglycaemia claims based on pooled…

2008
year
AUTH/2130/6/08 Pfizer Clause 4.1

Pfizer Toviaz journal advertisement: prescribing information missing for promoted tolterodine (Detrusitol)

A GP complained that a Toviaz ad also promoted tolterodine without prescribing information. The Panel ruled a breach for missing…

2009
year
AUTH/2213/3/09 Boehringer Ingelheim Clause 12.1 Clause 2

Anonymous doctor v Lilly and Boehringer Ingelheim: sponsored journal supplement found to be disguised promotion

A journal-lookalike supplement reporting a company-run symposium was presented as a sponsored independent forum report. The Panel ruled it was…

2009
year
AUTH/2203/1/09 Pfizer

Pfizer Champix ad: superiority claim vs NRT ruled misleading due to lack of study context (AUTH/2203/1/09)

A Champix journal ad claimed significantly greater quit success vs NiQuitin patch. PMCPA ruled the claim misleading because the ad…

2019
year
AUTH/3180/4/19 AstraZeneca Clause 1 Clause 2

AstraZeneca sales manager’s personal Instagram post about KOL nurse ruled in scope and unethical; conflict of interest not declared (AUTH/3180/4/19)

A respiratory nurse complained about a sales manager’s personal Facebook/Instagram posts referencing a nurse KOL. Panel found one Instagram post…

2008
year
AUTH/2176/10/08 Schering-Plough ⭐ Case of the Week

AUTH/2176/10/08: Nurse v Schering-Plough — alleged confidentiality breach in NHS infusion service programme (No breach)

A nurse alleged she was suspended for refusing to share confidential unit/customer data from an infusion service facilitation programme. The…

2008
year
AUTH/2167/9/08 Pfizer Clause 7.10 Clause 7.2 Clause 7.3

AUTH/2167/9/08: Astellas v Pfizer — Toviaz promotion, post hoc superiority claim and “new step” messaging

Pfizer’s Toviaz ad claimed superiority vs tolterodine based on post hoc analysis and used “a new step” wording. PMCPA ruled…

2009
year
AUTH/2251/7/09 Cephalon

AUTH/2251/7/09: Health professional v Cephalon (Effentora) – alleged off-label promotion (sublingual use) – No breach

A health professional alleged Cephalon reps promoted sublingual Effentora (off-licence). Panel found insufficient evidence on balance of probabilities; no breach…

2009
year
AUTH/2230/5/09 AstraZeneca

AUTH/2230/5/09: Anonymous v AstraZeneca — alleged conflict of interest/inducement via rep’s private supplies business (No breach)

Anonymous GP alleged an AstraZeneca rep offered savings via his private consumables company, creating a perceived inducement/conflict. Panel had concerns…

2009
year
AUTH/2283/12/09 Lundbeck Clause 4.7

AUTH/2283/12/09: Lundbeck breached Clause 4.7 over prescribing information location statement size/placement in Cipralex ad

A Cipralex (escitalopram) journal ad said “For references and prescribing information, see overleaf” in text smaller than the Code’s 2mm…

2009
year
AUTH/2289/12/09 Alcon Laboratories ⭐ Case of the Week

AUTH/2289/12/09: Merck Sharp & Dohme v Alcon — Azarga “comfort” leavepiece and over-emphasis claims

Alcon’s Azarga leavepiece repeatedly used “comfort/comfortable”. Appeal Board allowed the comparative “Significantly more comfortable than Cosopt” claim (with data), but…

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Filter by any clause or company

Members can instantly filter all 2,000+ cases by any of the 154 PMCPA clauses and 291 pharmaceutical companies — plus get video walkthroughs, expert podcasts and CPD certificates for every case.

154
Clauses to filter by
291
Companies to filter by
2,000+
Searchable cases
See plans from £299/year Sign in
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training